COVID-19 vaccine immunogenicity in people with HIV
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc..
OBJECTIVES: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Our objective was to compare COVID-19 vaccine immunogenicity in PWH to HIV-negative individuals.
DESIGN: In a Canadian multi-center prospective, observational cohort of PWH receiving at least two COVID-19 vaccinations, we measured vaccine-induced immunity at 3 and 6 months post 2nd and 1-month post 3rd doses.
METHODS: The primary outcome was the percentage of PWH mounting vaccine-induced immunity [co-positivity for anti-IgG against SARS-CoV2 Spike(S) and receptor-binding domain proteins] 6 months post 2nd dose. Univariable and multivariable logistic regressions were used to compare COVID-19-specific immune responses between groups and within subgroups.
RESULTS: Data from 294 PWH and 267 controls were analyzed. Immunogenicity was achieved in over 90% at each time point in both groups. The proportions of participants achieving comparable anti-receptor-binding domain levels were similar between the group at each time point. Anti-S IgG levels were similar by group at month 3 post 2nd dose and 1-month post 3rd dose. A lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose [92% vs. 99%; odds ratio: 0.14 (95% confidence interval: 0.03, 0.80; P = 0.027)]. In multivariable analyses, neither age, immune non-response, multimorbidity, sex, vaccine type, or timing between doses were associated with reduced IgG response.
CONCLUSION: Vaccine-induced IgG was elicited in the vast majority of PWH and was overall similar between groups. A slightly lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose demonstrating the importance of timely boosting in this population.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
AIDS (London, England) - 37(2023), 1 vom: 01. Jan., Seite F1-F10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Costiniuk, Cecilia T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AIDS Vaccines |
|---|
| Anmerkungen: |
Date Completed 15.12.2022 Date Revised 03.04.2023 published: Print-Electronic ClinicalTrials.gov: NCT04894448 ErratumIn: AIDS. 2023 Mar 1;37(3):559. - PMID 36695370 Citation Status MEDLINE |
|---|
| doi: |
10.1097/QAD.0000000000003429 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349888558 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349888558 | ||
| 003 | DE-627 | ||
| 005 | 20231226043711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/QAD.0000000000003429 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM349888558 | ||
| 035 | |a (NLM)36476452 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Costiniuk, Cecilia T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 vaccine immunogenicity in people with HIV |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2022 | ||
| 500 | |a Date Revised 03.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04894448 | ||
| 500 | |a ErratumIn: AIDS. 2023 Mar 1;37(3):559. - PMID 36695370 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a OBJECTIVES: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Our objective was to compare COVID-19 vaccine immunogenicity in PWH to HIV-negative individuals | ||
| 520 | |a DESIGN: In a Canadian multi-center prospective, observational cohort of PWH receiving at least two COVID-19 vaccinations, we measured vaccine-induced immunity at 3 and 6 months post 2nd and 1-month post 3rd doses | ||
| 520 | |a METHODS: The primary outcome was the percentage of PWH mounting vaccine-induced immunity [co-positivity for anti-IgG against SARS-CoV2 Spike(S) and receptor-binding domain proteins] 6 months post 2nd dose. Univariable and multivariable logistic regressions were used to compare COVID-19-specific immune responses between groups and within subgroups | ||
| 520 | |a RESULTS: Data from 294 PWH and 267 controls were analyzed. Immunogenicity was achieved in over 90% at each time point in both groups. The proportions of participants achieving comparable anti-receptor-binding domain levels were similar between the group at each time point. Anti-S IgG levels were similar by group at month 3 post 2nd dose and 1-month post 3rd dose. A lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose [92% vs. 99%; odds ratio: 0.14 (95% confidence interval: 0.03, 0.80; P = 0.027)]. In multivariable analyses, neither age, immune non-response, multimorbidity, sex, vaccine type, or timing between doses were associated with reduced IgG response | ||
| 520 | |a CONCLUSION: Vaccine-induced IgG was elicited in the vast majority of PWH and was overall similar between groups. A slightly lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose demonstrating the importance of timely boosting in this population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a AIDS Vaccines |2 NLM | |
| 700 | 1 | |a Singer, Joel |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Terry |e verfasserin |4 aut | |
| 700 | 1 | |a Langlois, Marc-André |e verfasserin |4 aut | |
| 700 | 1 | |a Arnold, Corey |e verfasserin |4 aut | |
| 700 | 1 | |a Galipeau, Yannick |e verfasserin |4 aut | |
| 700 | 1 | |a Needham, Judy |e verfasserin |4 aut | |
| 700 | 1 | |a Kulic, Iva |e verfasserin |4 aut | |
| 700 | 1 | |a Jenabian, Mohammad-Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Burchell, Ann N |e verfasserin |4 aut | |
| 700 | 1 | |a Shamji, Hasina |e verfasserin |4 aut | |
| 700 | 1 | |a Chambers, Catharine |e verfasserin |4 aut | |
| 700 | 1 | |a Walmsley, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Ostrowski, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Kovacs, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Darrell H S |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a Hull, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Brumme, Zabrina L |e verfasserin |4 aut | |
| 700 | 1 | |a Lapointe, Hope R |e verfasserin |4 aut | |
| 700 | 1 | |a Brockman, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Margolese, Shari |e verfasserin |4 aut | |
| 700 | 1 | |a Mandarino, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Samarani, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Vulesevic, Branka |e verfasserin |4 aut | |
| 700 | 1 | |a Lebouché, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Angel, Jonathan B |e verfasserin |4 aut | |
| 700 | 1 | |a Routy, Jean-Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, Curtis L |e verfasserin |4 aut | |
| 700 | 1 | |a Anis, Aslam H |e verfasserin |4 aut | |
| 700 | 0 | |a COVAXHIV Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AIDS (London, England) |d 1988 |g 37(2023), 1 vom: 01. Jan., Seite F1-F10 |w (DE-627)NLM012619280 |x 1473-5571 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:F1-F10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/QAD.0000000000003429 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 1 |b 01 |c 01 |h F1-F10 | ||